Vendor, Evanston, IL
Riptide Therapeutics LLC
UEI C95RHLDBCVB9, CAGE 97YF2
1 award and $0 obligated between March 1, 2024 and January 14, 2026, 100% under full and open competition, against 7.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91023C00035Definitive Contract, March 1, 2024, Full and Open Competition After Exclusion of Sources, 7 offers | NIH NCINational Institutes of Health | SBIR Topic #446 Phase I -Development of Senotherapeutic Agents for Cancer TreatmentNAICS 541715, PSC AN11 | $0 |
- Places of performance
- Illinois
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 6 across 1 awards